oxybutynin has been researched along with Hypogonadism in 6 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Hypogonadism: Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events." | 3.30 | Cardiovascular Safety of Testosterone-Replacement Therapy. ( Basaria, S; Bhasin, S; Boden, WE; Chan, A; Cunningham, GR; Davey, D; Dubcenco, E; Flevaris, P; Granger, CB; Huang, B; Kalahasti, V; Khan, N; Khera, M; Li, X; Lincoff, AM; Miller, MG; Mitchell, LM; Nissen, SE; Pencina, KM; Snabes, MC; Thompson, IM; Travison, TG; Wang, Q; Wolski, K; Yi, T, 2023) |
| "Male hypogonadism has been treated with exogenous testosterone since the 1930s." | 2.52 | Transdermal delivery of testosterone. ( Hadgraft, J; Lane, ME, 2015) |
| "Male hypogonadism is a condition characterized by inadequate testicular production of sex steroids and sperms; however, the term is more commonly used to identify testosterone (T) deficiency." | 2.47 | Update in testosterone therapy for men. ( Corona, G; Forti, G; Maggi, M; Rastrelli, G, 2011) |
| " They represent an improvement compared with transdermal delivery by patches because they offer more dosage flexibility, less irritation potential and a better cosmetic appearance." | 2.43 | Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. ( Alberti, I; Carrara, DN; Grenier, A; Kraus, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alberti, I | 1 |
| Grenier, A | 1 |
| Kraus, H | 1 |
| Carrara, DN | 1 |
| Lincoff, AM | 1 |
| Bhasin, S | 1 |
| Flevaris, P | 1 |
| Mitchell, LM | 1 |
| Basaria, S | 1 |
| Boden, WE | 1 |
| Cunningham, GR | 1 |
| Granger, CB | 1 |
| Khera, M | 1 |
| Thompson, IM | 1 |
| Wang, Q | 1 |
| Wolski, K | 1 |
| Davey, D | 1 |
| Kalahasti, V | 1 |
| Khan, N | 1 |
| Miller, MG | 1 |
| Snabes, MC | 1 |
| Chan, A | 1 |
| Dubcenco, E | 1 |
| Li, X | 1 |
| Yi, T | 1 |
| Huang, B | 1 |
| Pencina, KM | 1 |
| Travison, TG | 1 |
| Nissen, SE | 1 |
| Hadgraft, J | 1 |
| Lane, ME | 1 |
| Corona, G | 1 |
| Rastrelli, G | 1 |
| Forti, G | 1 |
| Maggi, M | 1 |
| Orme, C | 1 |
| Imaeda, S | 1 |
| Mauras, N | 1 |
| Torres-Santiago, L | 1 |
| Taboada, M | 1 |
| Santen, R | 1 |
4 reviews available for oxybutynin and Hypogonadism
| Article | Year |
|---|---|
Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery.
Topics: Administration, Cutaneous; Alprazolam; Animals; Anti-Anxiety Agents; Drug Delivery Systems; Estradio | 2005 |
Transdermal delivery of testosterone.
Topics: Administration, Cutaneous; Androgens; Gels; Humans; Hypogonadism; Male; Skin Absorption; Testosteron | 2015 |
Update in testosterone therapy for men.
Topics: Administration, Oral; Delayed-Action Preparations; Humans; Hypogonadism; Injections, Intramuscular; | 2011 |
Estrogen therapy in Turner syndrome: does the type, dose and mode of delivery matter?
Topics: Administration, Cutaneous; Administration, Oral; Child; Estradiol; Estrogen Replacement Therapy; Est | 2012 |
1 trial available for oxybutynin and Hypogonadism
| Article | Year |
|---|---|
Cardiovascular Safety of Testosterone-Replacement Therapy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Ge | 2023 |
1 other study available for oxybutynin and Hypogonadism
| Article | Year |
|---|---|
Images in clinical medicine. Eschar formation from testosterone patch.
Topics: Administration, Cutaneous; Aged; Humans; Hypogonadism; Male; Skin; Testosterone; Transdermal Patch | 2012 |